Vigil Neuroscience
Cambridge
About Vigil Neuroscience
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $180.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: nasdaq:VIGL
- Website: vigilneuro.com
- Phone: 857-254-4445
Industries & Categories
Biotechnology, Health Care, Life Science, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vigil-neuroscience-54090 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.